StephanABartSr.MD

Family Medicine • Woodstock, MD

Physician

Join to view full profile

Dr. Bart is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bart's full profile

Already have an account?

Office
10403 Wetherburn Rd
Woodstock, MD 21163
Phone+1 352-586-8547
Is this information wrong?

Education & Training

Bayfront Health St PetersburgResidency, Family Medicine, 1992 - 1995
Rush Medical College of Rush University Medical CenterClass of 1992

Certifications & Licensure

FL State Medical License 1993 - 2026
MD State Medical License 2006 - 2024
PA State Medical License 2005 - 2006
American Board of Family Medicine Family Medicine

Clinical Trials

Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650 Start of enrollment: 2006 Aug 01
Completed
Phase 1
Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects Start of enrollment: 2008 Feb 01
Completed
Phase 1
Multiple-Dose Study of VGX-1027 in Healthy Subjects Start of enrollment: 2008 Sep 01
Completed
Phase 1
Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers Start of enrollment: 2010 Mar 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
Christy A Comeaux, Stephan Bart, Arangassery Rosemary Bastian, Vladislav Klyashtornyy, Els De Paepe, Edmund Omoruyi, Leslie van der Fits, Roy van Heesbeen, Esther Heij...> ;The Journal of Infectious Diseases. 2024 Jan 12
4 citations
A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.
Christine A Shaw, Allison August, Stephan Bart, Peta-Gay Jackson Booth, Conor Knightly, Trevor Brasel, Scott C Weaver, HongHong Zhou, Lori Panther> ;Vaccine. 2023 Jun 13
18 citations
Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
Neil Goldstein, Viki Bockstal, Stephan Bart, Kerstin Luhn, Cynthia Robinson, Auguste Gaddah, Benoit Callendret, Macaya Douoguih> ;The Journal of Infectious Diseases. 2020 Sep 16
3 citations
A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever
Robert T. Cartee, Ann Thanawastien, Thomas J. Griffin, John J. Mekalanos, Stephan Bart, Kevin P. Killeen> ;Plos Neglected Tropical Diseases. 2020 Jan 6
36 citations
Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study
Stephan Bart, Kevin Cannon, Darrell Herrington, Richard Mills, Eduardo Forleo-Neto, Kelly Lindert, Ahmed Abdul Mateen> ;Human Vaccines & Immunotherapeutics. 2016 Jun 20
74 citations
A Cell Culture–Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults
Stephan A. Bart, Matthew Hohenboken, Giovanni Della Cioppa, Vas Narasimhan, Philip R. Dormitzer, Niranjan Kanesa-thasan> ;Science Translational Medicine. 2014 Apr 30
14 citations
Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, pa...
Stephan Bart, Joachim Marr, Konstanze Diefenbach, Dietmar Trummer, Carole Sampson-Landers> ;Contraception. 2012 Jan 1
Join now to see all

StephanABartSr.MD

Dr. Bart is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.